Kelly Lawrence W & Associates’s Biogen BIIB Stock Holding History

Kelly Lawrence W & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-8	Closed	-$2K	–	141
2017 Q1	$2K	Buy	+8	New	+$2.26K	﹤0.01%	156

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kelly Lawrence W & Associates's BIIB Position: Q2 2017 in Review

Kelly Lawrence W & Associates sold out of Biogen (BIIB) in Q2 2017, closing a stake of 8 shares — an estimated $2K sold.

Kelly Lawrence W & Associates first reported a position in BIIB in Q1 2017 and held it in 1 quarter. The position peaked at $2K in Q1 2017. 992 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

Kelly Lawrence W & Associates reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
Kelly Lawrence W & Associates sold 8 Biogen shares in Q2 2017, an estimated $2K.
Kelly Lawrence W & Associates first reported a position in Biogen in Q1 2017 and held it in 1 quarter.
Kelly Lawrence W & Associates's Biogen position peaked at $2K in Q1 2017.
992 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Kelly Lawrence W & Associates's 13F filing for Q2 2017, filed 1 Aug 2017.